


## Global burden of disease in men and women .

Estimate rate of genital warts by gender: 54% men, 46% women. 5

1. Vaccine 2012; (Suppl5): F12
2. WHO. Available In: [http://www.who.int/whe/1995/media\\_centre/executive\\_summary/en/index.html](http://www.who.int/whe/1995/media_centre/executive_summary/en/index.html) Consult March 12, 2013
3. J Clin Microbiol 1995;33:2058
4. WHO. Available In: [http://whp1b.doc.who.int/hp/2007WHO\\_V8\\_07\\_05.ang.pdf](http://whp1b.doc.who.int/hp/2007WHO_V8_07_05.ang.pdf) Consult March 12, 2013
5. Health Protect Rep 2012;69



## Study of Guiliano et al.

*The NEW ENGLAND JOURNAL of MEDICINE*

ESTABLISHED IN 1812 FEBRUARY 3, 2011 VOL. 364 NO.5

### Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males

Anna R. Giuliano, Ph. D., Joel M. Palefsky, M.D., Stephen Goldstone, M.D., Edson D. Moreira, Jr., M.D., Mary E. Penny, M.D., Carlos Aranda, M.D., Eftyhia Vardas, M.D. Harald Moi, M.D., Heiko Jessen, M.D., Richard Hillman, M.D., Yen-Hwa Chang, M.D., Daron Ferris, M.D., Danielle Rouleau, M, M.D., Janine Bryan, Ph. D., J. Brooke Marshall, Ph.D., Scott Vuocolo, Ph.D., Eliav Barr, M.D., David Radley, M.S., Richard M. Haupt, M.D., and Dalya Guris, M.D.

## Study of Insiaga et al.




Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: A transmission dynamic model based evaluation


Ralpe P. Insiaga<sup>a</sup>, Erik J. Dasbach<sup>a</sup>, Elamin H. Elbasha<sup>a</sup>, Andrea Puig<sup>a</sup>, Luz Myriam Reynales - Shigematsu<sup>a</sup>

Incremental cost-effectiveness ratios in the primary analyses ranged from - \$3000 (U.S.) per quality-adjusted life year (QALY) gained for female vaccination strategies to - \$1600 (QALY) for a adding male vaccination with catch-up.

### Impact of strategies of vaccination on incidence of cervicancer. (HPV 16 and 18)



### Impact of strategies of vaccination on incidence of genital warts (HPV 6 and 11).



## Periods to notice expected benefits after the introduction of vaccination against HPV.

### Indicators of Impact

Short term (months)


- Rates of infection with HPV
- Incidence of genital warts

Medium term (years)

- Decline of incidence of cervical lesions (dysplasias)

Long term (decades)

- Decline in incidence and mortality of cervical, vulvar, vaginal, anal, and oropharyngeal cancers.



## Recommendations of CDC

Recommended Immunization schedule for persons aged 0 through 18 years - United States, 2016.

These recommendations must be read with the footnotes that follow. For those who fall behind or state late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in figure 1. To determine minimum intervals between doses, see the catch-up schedule. School entry and adolescent vaccine age groups are shaded.

Vaccine	Age Group	Year	Notes
MM2	12-17	2011	MM2 (MM1 + M2)
MM2	18-64	2011	MM2 (MM1 + M2)
MM2	65-77	2011	MM2 (MM1 + M2)
MM2	78-89	2011	MM2 (MM1 + M2)
MM2	90-99	2011	MM2 (MM1 + M2)
MM2	100	2011	MM2 (MM1 + M2)
MM2	101	2011	MM2 (MM1 + M2)
MM2	102	2011	MM2 (MM1 + M2)
MM2	103	2011	MM2 (MM1 + M2)
MM2	104	2011	MM2 (MM1 + M2)
MM2	105	2011	MM2 (MM1 + M2)
MM2	106	2011	MM2 (MM1 + M2)
MM2	107	2011	MM2 (MM1 + M2)
MM2	108	2011	MM2 (MM1 + M2)
MM2	109	2011	MM2 (MM1 + M2)
MM2	110	2011	MM2 (MM1 + M2)
MM2	111	2011	MM2 (MM1 + M2)
MM2	112	2011	MM2 (MM1 + M2)
MM2	113	2011	MM2 (MM1 + M2)
MM2	114	2011	MM2 (MM1 + M2)
MM2	115	2011	MM2 (MM1 + M2)
MM2	116	2011	MM2 (MM1 + M2)
MM2	117	2011	MM2 (MM1 + M2)
MM2	118	2011	MM2 (MM1 + M2)
MM2	119	2011	MM2 (MM1 + M2)
MM2	120	2011	MM2 (MM1 + M2)
MM2	121	2011	MM2 (MM1 + M2)
MM2	122	2011	MM2 (MM1 + M2)
MM2	123	2011	MM2 (MM1 + M2)
MM2	124	2011	MM2 (MM1 + M2)
MM2	125	2011	MM2 (MM1 + M2)
MM2	126	2011	MM2 (MM1 + M2)
MM2	127	2011	MM2 (MM1 + M2)
MM2	128	2011	MM2 (MM1 + M2)
MM2	129	2011	MM2 (MM1 + M2)
MM2	130	2011	MM2 (MM1 + M2)
MM2	131	2011	MM2 (MM1 + M2)
MM2	132	2011	MM2 (MM1 + M2)
MM2	133	2011	MM2 (MM1 + M2)
MM2	134	2011	MM2 (MM1 + M2)
MM2	135	2011	MM2 (MM1 + M2)
MM2	136	2011	MM2 (MM1 + M2)
MM2	137	2011	MM2 (MM1 + M2)
MM2	138	2011	MM2 (MM1 + M2)
MM2	139	2011	MM2 (MM1 + M2)
MM2	140	2011	MM2 (MM1 + M2)
MM2	141	2011	MM2 (MM1 + M2)
MM2	142	2011	MM2 (MM1 + M2)
MM2	143	2011	MM2 (MM1 + M2)
MM2	144	2011	MM2 (MM1 + M2)
MM2	145	2011	MM2 (MM1 + M2)
MM2	146	2011	MM2 (MM1 + M2)
MM2	147	2011	MM2 (MM1 + M2)
MM2	148	2011	MM2 (MM1 + M2)
MM2	149	2011	MM2 (MM1 + M2)
MM2	150	2011	MM2 (MM1 + M2)
MM2	151	2011	MM2 (MM1 + M2)
MM2	152	2011	MM2 (MM1 + M2)
MM2	153	2011	MM2 (MM1 + M2)
MM2	154	2011	MM2 (MM1 + M2)
MM2	155	2011	MM2 (MM1 + M2)
MM2	156	2011	MM2 (MM1 + M2)
MM2	157	2011	MM2 (MM1 + M2)
MM2	158	2011	MM2 (MM1 + M2)
MM2	159	2011	MM2 (MM1 + M2)
MM2	160	2011	MM2 (MM1 + M2)
MM2	161	2011	MM2 (MM1 + M2)
MM2	162	2011	MM2 (MM1 + M2)
MM2	163	2011	MM2 (MM1 + M2)
MM2	164	2011	MM2 (MM1 + M2)
MM2	165	2011	MM2 (MM1 + M2)
MM2	166	2011	MM2 (MM1 + M2)
MM2	167	2011	MM2 (MM1 + M2)
MM2	168	2011	MM2 (MM1 + M2)
MM2	169	2011	MM2 (MM1 + M2)
MM2	170	2011	MM2 (MM1 + M2)
MM2	171	2011	MM2 (MM1 + M2)
MM2	172	2011	MM2 (MM1 + M2)
MM2	173	2011	MM2 (MM1 + M2)
MM2	174	2011	MM2 (MM1 + M2)
MM2	175	2011	MM2 (MM1 + M2)
MM2	176	2011	MM2 (MM1 + M2)
MM2	177	2011	MM2 (MM1 + M2)
MM2	178	2011	MM2 (MM1 + M2)
MM2	179	2011	MM2 (MM1 + M2)
MM2	180	2011	MM2 (MM1 + M2)
MM2	181	2011	MM2 (MM1 + M2)
MM2	182	2011	MM2 (MM1 + M2)
MM2	183	2011	MM2 (MM1 + M2)
MM2	184	2011	MM2 (MM1 + M2)
MM2	185	2011	MM2 (MM1 + M2)
MM2	186	2011	MM2 (MM1 + M2)
MM2	187	2011	MM2 (MM1 + M2)
MM2	188	2011	MM2 (MM1 + M2)
MM2	189	2011	MM2 (MM1 + M2)
MM2	190	2011	MM2 (MM1 + M2)
MM2	191	2011	MM2 (MM1 + M2)
MM2	192	2011	MM2 (MM1 + M2)
MM2	193	2011	MM2 (MM1 + M2)
MM2	194	2011	MM2 (MM1 + M2)
MM2	195	2011	MM2 (MM1 + M2)
MM2	196	2011	MM2 (MM1 + M2)
MM2	197	2011	MM2 (MM1 + M2)
MM2	198	2011	MM2 (MM1 + M2)
MM2	199	2011	MM2 (MM1 + M2)
MM2	200	2011	MM2 (MM1 + M2)